Health care · Historical news and closing prices
UBS Group AG and its related bodies corporate became a substantial holder in Artrya, reporting voting power of just over 5%. The disclosed interests include fund management and securities-borrowing and lending arrangements; the filing does not establish these as outright purchases.
Closing price · 2026-10-27: $2.60 · +5.69%
Artrya says Huntsville Hospital Health System, its largest customer to date, has signed a five-year commercial agreement, marking the first SAPPHIRE study participant to convert to a customer; the deal includes a minimum commitment of about US$500,000. The company also reported materially higher Salix Coronary Plaque use at Tanner Health after introducing a pre-authorisation workflow, with elevated activity continuing into October, while it will conduct an additional reader study before filing for FDA clearance of Salix Coronary Flow, later than previously expected. Artrya reported pro forma cash of about $67 million at quarter-end, with an additional research and development rebate claim of about $5 million in process.
Closing price · 2026-10-26: $2.46 · +0.41%